Literature DB >> 19224298

Long-term follow-up of patients with fulminant Clostridium difficile colitis.

Aaron T Miller1, Parissa Tabrizian, Alexander J Greenstein, Andrew Dikman, John Byrn, Celia Divino.   

Abstract

PURPOSE: The purpose of this study was to determine the long-term survival rate, rate of gastrointestinal continuity restoration, and rate of recurrence following an attack of fulminant Clostridium difficile colitis.
MATERIAL AND METHODS: Fulminant C. difficile colitis was defined as any patient who had a bout of C. difficile colitis and required surgical intervention after failing medical therapy. These patients were found through a pathological database search. Follow-up phone calls were made to any patient who survived at least 30 days after being discharged from the hospital following surgical intervention (long-term survivor group).
RESULTS: A total of 49 patients were involved in the study. The 30-day mortality rate was 57% (28/49), with an in-hospital mortality rate of 49%. The 5-year survival rate for the long-term survival group was 38% (8/21) and 16.3% for all patients. Gastrointestinal continuity was restored in 20% of the patients. There was one documented recurrence of C. difficile colitis
CONCLUSION: Patients who have a bout of fulminant C. difficile colitis have a poor prognosis of surviving longer than 5 years. Restoring gastrointestinal continuity is uncommon and usually reserved for patients with few co-morbidities. Recurrent C. difficile colitis after surgical resection is a rare occurrence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224298     DOI: 10.1007/s11605-009-0819-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  13 in total

Review 1.  Clostridium difficile-associated diarrhea and colitis.

Authors:  S F Yassin; T M Young-Fadok; N N Zein; D S Pardi
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

2.  Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain.

Authors:  François Lamontagne; Annie-Claude Labbé; Olivier Haeck; Olivier Lesur; Mathieu Lalancette; Carlos Patino; Martine Leblanc; Michel Laverdière; Jacques Pépin
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  The outcome of surgery in fulminant Clostridium difficile colitis.

Authors:  K Koss; M A Clark; D S A Sanders; D Morton; M R B Keighley; J Goh
Journal:  Colorectal Dis       Date:  2006-02       Impact factor: 3.788

4.  Risk factors for the development of fulminant Clostridium difficile colitis.

Authors:  Alexander J Greenstein; John C Byrn; Linda P Zhang; Kristin A Swedish; Alice E Jahn; Celia M Divino
Journal:  Surgery       Date:  2008-03-24       Impact factor: 3.982

5.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

Review 6.  Fulminant Clostridium difficile colitis.

Authors:  Sasha D Adams; David W Mercer
Journal:  Curr Opin Crit Care       Date:  2007-08       Impact factor: 3.687

7.  Clostridium difficile infection: a surgical disease in evolution.

Authors:  Joshua L Hermsen; Cosmin Dobrescu; Kenneth A Kudsk
Journal:  J Gastrointest Surg       Date:  2008-07-09       Impact factor: 3.452

8.  The burden of Clostridium difficile in surgical patients in the United States.

Authors:  Marc Zerey; B Lauren Paton; Amy E Lincourt; Keith S Gersin; Kent W Kercher; B Todd Heniford
Journal:  Surg Infect (Larchmt)       Date:  2007-12       Impact factor: 2.150

9.  Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States.

Authors:  Rocco Ricciardi; David A Rothenberger; Robert D Madoff; Nancy N Baxter
Journal:  Arch Surg       Date:  2007-07

10.  Outcome after colectomy for Clostridium difficile colitis.

Authors:  Walter E Longo; John E Mazuski; Katherine S Virgo; Paul Lee; Anil N Bahadursingh; Frank E Johnson
Journal:  Dis Colon Rectum       Date:  2004-10       Impact factor: 4.585

View more
  8 in total

1.  Fulminant Clostridium difficile colitis in a post-liver transplant patient.

Authors:  Maximilian Lee; Andrew A Shelton; Waldo L Concepcion; Clark A Bonham; Tami J Daugherty
Journal:  Dig Dis Sci       Date:  2010-07-16       Impact factor: 3.199

2.  Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level.

Authors:  David B Stewart; Christopher S Hollenbeak
Journal:  J Gastrointest Surg       Date:  2011-09       Impact factor: 3.452

3.  Toxic megacolon from hypervirulent Clostridium difficile infection (ribotype 027) following elective total knee replacement: an emerging challenge in modern health care.

Authors:  Buchi Rajendra Babu Arumilli; Prasanthi Koneru; Irfan Fayyaz
Journal:  BMJ Case Rep       Date:  2010-01-13

4.  CAGS and ACS evidence based reviews in surgery. Is a diverting loop ileostomy and colonic lavage an alternative to colectomy for the treatment of severe Clostridium difficile-associated disease?

Authors:  Carl J Brown; Marylise Boutros; Andrew Morris; Celia M Divino
Journal:  Can J Surg       Date:  2014-06       Impact factor: 2.089

Review 5.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

6.  Toxic megacolon associated Clostridium difficile colitis.

Authors:  Leena Sayedy; Darshan Kothari; Robert J Richards
Journal:  World J Gastrointest Endosc       Date:  2010-08-16

Review 7.  zzm321990 Clostridioides difficile Infection, Still a Long Way to Go.

Authors:  Eleftheria Kampouri; Antony Croxatto; Guy Prod'hom; Benoit Guery
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

Review 8.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.